Catalyst ligands

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%.

118949-61-4, The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

5144-89-8, 1,10-Phenanthroline hydrate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example I 2,9-bis(4methylphenyl)-1,10-phenanthroline (2). A 1.7 M solution of t-butyllithium in pentane (300 mL, 0.510 mol) was added under argon to a stirred suspension of p-iodotoluene (56.04 g, 0.257 mol) in ether (150 mL) at -78 C. The mixture was allowed to warm to room temperature over 1 h. The resulting solution of tolyllithium was added to a solution of 1,10-phenanthroline monohydrate (8.50 g, 0.043 mol) in toluene (100 mL). The resulting dark red solution was stirred under argon for 48 h. The reaction was carefully quenched with water (300 mL) and extracted with CH2 Cl2 (3*150 mL). The combined organic layers were dried (Na2 SO4) and evaporated to a volume of 500 mL under reduced pressure. The solution of crude product was oxidized by stirring with activated MnO2 (60 g). An additional portion of MnO2 (30 g) was added to the reaction after 1 h to ensure complete oxidation. After a total of 2 h, anhydrous MgSO4 (40 g) was added, and the mixture was filtered. The MnO2 /MgSO4 was washed with CH2 Cl2 (300 mL), and the solvent was concentrated to a volume of 50 mL, when a crystalline solid formed. The solution was cooled in ice and filtered. The light yellow product crystals were filtered, washed with one portion of cold toluene (20 mL), and dried. Yield 8.63 g 56%). 1 H NMR (CDCl3) delta8.38 (d, J=8.1 Hz, 4H), 8.29 (d, J=8.5 Hz, 2H), 8.13 (d, J=8.4 Hz, 2H), 7.77 (s, 2H), 7.40 (d, J=8.1 Hz, 4H), 2.47 (s, 6H)., 5144-89-8

As the paragraph descriping shows that 5144-89-8 is playing an increasingly important role.

Reference：
Patent; University of Pittsburgh of the Commonwealth System of Higher Education; US5998594; (1999); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3002-77-5,2-Methyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

0.29 g of Cu (NO3) 2 · 3H2O and 0.174 g of 2-methyl-1,10-phenanthroline were sequentially added to a mixed solution of 25 mL of methanol and 25 mL of acetonitrile,Stir constantly.After 8 hours the reaction was filtered,The mother liquor with ether diffusion,Let stand at room temperature,Several days to give a green bulk crystal Z5., 3002-77-5

As the paragraph descriping shows that 3002-77-5 is playing an increasingly important role.

Reference：
Patent; Capital Normal University; Lu Xiaoming; (52 pag.)CN106543209; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3002-77-5,2-Methyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

0.29 g of Cu (NO3) 2 · 3H2O and 0.174 g of 2-methyl-1,10-phenanthroline were sequentially added to a mixed solution of 25 mL of methanol and 25 mL of acetonitrile,Stir constantly.After 8 hours the reaction was filtered,The mother liquor with ether diffusion,Let stand at room temperature,Several days to give a green bulk crystal Z5., 3002-77-5

As the paragraph descriping shows that 3002-77-5 is playing an increasingly important role.

Reference：
Patent; Capital Normal University; Lu Xiaoming; (52 pag.)CN106543209; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1148-79-4, 2,2′:6′,2”-Terpyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

UO2Cl2(terpy) (3): A mixture of 1.7 ml (0.2 mmol) UCl4/HCl 0.12 M, 93 mg (0.4 mmol) 2,2???:6???,2???-terpyridine, 2.3 ml (19 mmol) acetonitrile and 1.1 ml (12 mmol) pyridine was placed in a Parr vessel and then heated statically at 120 ?°C for 48 h. The resulting yellow product was then filtered off, washed with water and dried at room temperature (reaction yield 79percent). XRD powder pattern indicated that the compound was obtained as a pure phase (Supplementary Information S3)., 1148-79-4

As the paragraph descriping shows that 1148-79-4 is playing an increasingly important role.

Reference：
Article; Lhoste, Jerome; Henry, Natacha; Loiseau, Thierry; Guyot, Yannick; Abraham, Francis; Polyhedron; vol. 50; 1; (2013); p. 321 – 327;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937.

22348-32-9, As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128249-70-7,2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

Cobalt(II) tetrafluoroborate hydrate (25mg, 0.0675mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant orange solution was stirred at room temperature for one hour. The product was precipitated using an excess of diethyl ether and the precipitate was collected by vacuum filtration, leaving an orange powder. A vapour diffusion of diethyl ether into a concentrated solution of the complex in acetonitrile gave orange crystals suitable for X-ray diffraction. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.6; H, 3.81; N, 8.53%: calcd for C46H38B2CoF8N6O4 C, 56.9; H, 3.94; N, 8.65%. 1H NMR (CD3CN): delta 2.7 (8H, Ph H2/6), 3.0 (4H, Ph H4), 7.7 (8H, Ph H3/5), 20.0 and 36.8 (both 4H, Ox H5), 40.5 (4H, Py H3/5), 84.7 (4H, Ox H4). No peak from the Py H4 proton environment was observed, which may be obscured by the CHD2CN solvent peak., 128249-70-7

The synthetic route of 128249-70-7 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

Solid [Co(H2O)6](ClO4)2 (10.0 mg, 21.8 lmol) was placed at thebottom of a 4.0 cm3 test tube with 0.50 cm3 of dmso. Then the tubewas slowly filled with 2.50 cm3 of a dmso?CH3OH mixture (1:4 v/v)containing terpy (15.0 mg, 64.4 lmol). Finally, 1 (15.0 mg,9.01 lmol) dissolved in 0.50 cm3 of CH3OH was placed on the topand the tube covered with parafilm. X-ray quality deep browncrystals of 2 were grown in the text tube by slow diffusion at roomtemperature during 25 days. Yield: 3.20 mg (1.30 lmol, 29percent). X-rayabsorption microanalysis for 2: 3:2 Co/Nb molar ratio. Elementalanalysis for C105H86N18O33Co3Nb2 (2490.52 g mol1) ? Exp. (Calc.):percentC 51.55 (50.94), percentH 3.02 (3.18), percentN 10.49 (10.32), percentCo 7.50 (7.30)percent.IR (KBr disk/cm1): 3475 [m(O?H)], 3062 and 2930 [m(C?H)], 1715and 1687 [mas(CO)], 1641 [m(CN)], 1470 and 1448 [m(CC)],1401 [ms(CO)], 905 [m(NbO] and 421 [m(CoAN)].

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Oliveira, Willian X.C.; Pereira, Cynthia L.M.; Pinheiro, Carlos B.; Krambrock, Klaus; Grancha, Thais; Moliner, Nicolas; Lloret, Francesc; Julve, Miguel; Polyhedron; vol. 117; (2016); p. 710 – 717;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, A solution of compound 9 (200mg, 0.39mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (212mg, 0.78mmol), and potassium hexafluorophosphate (108mg, 0.585mmol) in dry 1,2-dichloroethane (20mL) was stirred at 40°C for 24h. The reaction mixture was concentrated under reduced pressure and the crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 10 as a dark red solid (198mg, 50percent). 1H NMR (300MHz, CDCl3): delta 8.88 (s, 1H), 8.83 (s, 1H), 8.75 (s, 2H), 8.27 (d, J=6Hz, 1H), 8.02 (dd, J=1.5Hz, 1.5Hz, 1H), 7.80 (d, J=5.4Hz, 1H), 7.84 (d, J=6.3Hz, 1H), 7.76(dd, J=1.5Hz, 1.5Hz, 1H), 7.69 (dd, J=1.5Hz, 1.5Hz, 1H), 7.59?7.64 (m, 5H), 7.30(d, J=5.4Hz, 1H), 7.01?7.16 (m, 1H), 6.89 (q, J=5.4Hz, 1H), 6.52 (q, J=7.8Hz, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 3.98 (s, 3H), 3.96 (s, 3H); 13C NMR (125MHz, CDCl3): delta 181.4, 164.3, 164.3, 164.1, 163.9, 162.1, 159.5 (d, JCF=252.1Hz), 157.9, 157.3, 156.6, 156.4, 155.4, 151.6, 150.7, 150.4, 145.6, 138.4, 137.2, 136.3, 135.8, 135.7, 135.4, 135.2, 128.1, 126.2, 126.1, 125.8, 125.7, 125.1, 122.8, 122.7, 122.1, 121.9, 121.6, 120.0, 119.0, 109.5 (d, JCF=22.7Hz), 53.4, 53.3, 53.2; HRMS (FAB): calcd. for C41H31FN5O8SRu [M+] 874.0921, found 874.0923.

71071-46-0 Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate 326419, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI